Phylinda L. S. Chan - Concepedia

Author

Phylinda L. S. Chan

Pfizer (United Kingdom)

Also Known As

P. L. S. Chan, Phylinda Chan, Phylinda L S Chan, Phylinda L. S. Chan, Phylinda L.S. Chan, Phylinda LS Chan

Publications

699

Citations

H-Index

Concepts

All Affiliations

Pfizer (United Kingdom)Pfizer (United States)University of Auckland Oregon Health & Science University Portland VA Medical Center

About

Phylinda L. S. Chan is an author at Pfizer (United Kingdom) specializing in medicine, neuroscience, and parkinson disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	338
2	Public Health	1	1	86
3	Social Sciences	1	1	28
4	Biostatistics	1	1	86
5	Epidemiology	1	1	86

Phylinda L. S. Chan

Publications

578

Citations

H-Index

Page 1

	Year	Citations
Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children Brian J. Anderson, Nicholas H. G. Holford, Gerald Woollard, British Journal of Clinical Pharmacology	1998	105
Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments Nicholas H. G. Holford, Phylinda L. S. Chan, John G. Nutt, Journal of Pharmacokinetics and Pharmacodynamics Neurodegenerative DiseasesDisease ProgressionMedicineParkinson DiseaseExperimental Neuropathology	2006	90
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects Phylinda L. S. Chan, Philippe Jacqmin, Marc Lavielle, Journal of Pharmacokinetics and Pharmacodynamics Viral Load DataMaraviroc MonotherapyNeurovirologyMonolix SoftwarePharmacology	2010	86
Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford Pharmaceutical Research Neurodegenerative DiseasesExternal ValidationLevodopa Slows ProgressionParkinson DiseaseNeuropharmacology	2007	61
Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford Journal of Pharmacokinetics and Pharmacodynamics Neurodegenerative DiseasesFirst FourPharmacodynamic ChangesParkinson DiseaseMedicine	2005	30
Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford Journal of Pharmacokinetics and Pharmacodynamics Neurodegenerative DiseasesLevodopa PharmacokineticsMedicineParkinson DiseaseParkinson ’	2005	30
Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford Journal of Pharmacokinetics and Pharmacodynamics NeurophysiologyExogenous LevodopaParkinson DiseaseMedicineNeuropharmacology	2004	28
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older Richard C. Franzese, Lynn McFadyen, Kenny J. Watson, Clinical Pharmacology & Therapeutics	2021	28
Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis John S. Bradley, Gregory G. Stone, Phylinda L. S. Chan, The Pediatric Infectious Disease Journal	2020	26
Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab From Adult Healthy Subjects to Pediatric Patients With Duchenne Muscular Disease Indranil Bhattacharya, Zorayr Manukyan, Phylinda L. S. Chan, The Journal of Clinical Pharmacology	2017	24

Page 1